Arcutis Biotherapeutics

Q3 FY2026 EarningsARQT.US Q3 FY26 results slightly beat revenue consensus but missed significantly on bottom-line expectations. Revenue reached $143.9M (+45% YoY) vs. $142.6M expected, driven by strong patient demand for ZORYVE foam. However, GAAP EPS of $0.06 was significantly below the $0.16 consensus mean, primarily due to a 60% YoY surge in SG&A expenses ($99.6M) and continued high R&D investments. While the company maintained GAAP profitability for the quarter, the variance highlights a heavy reinvestment phase to support commercial expansion and pipeline development.